Best of ASCO - 2014 Annual Meeting



Attend this session at the
2018 ASCO Annual Meeting!

Session: Hematologic Malignancies—Plasma Cell Dyscrasia

Type: Oral Abstract Session

Time: Friday June 1, 2:45 PM to 5:45 PM

Location: E450

Daratumumab (DARA) in combination with carfilzomib and dexamethasone (D-Kd) in lenalidomide (Len)-refractory patients (Pts) with relapsed multiple myeloma (MM): Subgroup analysis of MMY1001.

Multiple Myeloma

Hematologic Malignancies—Plasma Cell Dyscrasia

2018 ASCO Annual Meeting

Abstract No:

J Clin Oncol 36, 2018 (suppl; abstr 8002)

Author(s): Ajai Chari, Joaquin Martinez-Lopez, Maria-Victoria Mateos, Joan Blade, Sagar Lonial, Lotfi Benboubker, Albert Oriol Rocafiguera, Bertrand Arnulf, Jesus San-Miguel, Luis Pineiro, Andrzej J. Jakubowiak, Carla De Boer, Jianping Wang, Jordan Mark Schecter, Philippe Moreau; Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY; Hospital-12-de-Octubre, Madrid, Spain; University Hospital of Salamanca/IBSAL, Salamanca, Spain; Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain; Winship Cancer Institute, Emory University, Atlanta, GA; Hôpital Bretonneau, Centre Hospitalier Régional Universitaire (CHRU), Tours, France; Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain; Hôpital Saint Louis, Paris, France; Clínica Universidad de Navarra-CIMA, IDISNA, CIBERONC, Pamplona, Spain; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX; University of Chicago Medical Center, Chicago, IL; Janssen Biologics, Leiden, Netherlands; Janssen Research & Development, LLC, Raritan, NJ; Hematology, University Hospital Hôtel-Dieu, Nantes, France

Abstract Disclosures


Background: Len-refractory pts have poor outcomes, highlighting an unmet medical need. In the phase 1b MMY1001 study (NCT01998971), D-Kd induced deep responses and was well tolerated in pts with relapsed MM. We examined the safety and efficacy of D-Kd in len-refractory pts. Methods: In total, 85 carfilzomib (carf)-naïve pts with 1-3 prior lines of therapy were enrolled. Pts received carf (20 mg/m2 on Cycle 1 Day 1 [C1D1] and 70 mg/m2 on C1D8+) on days 1, 8, and 15 of 28-day cycles and dexamethasone 40 mg QW. DARA was given QW C1-C2, Q2W C3-C6, and Q4W thereafter; 10 pts received a standard first dose of DARA (16 mg/kg) on C1D1, and 75 pts received a split first dose of DARA (8 mg/kg on C1D1 and C1D2). Refractoriness was defined as progression ≤60 days of completion of last line of therapy. Results: Among len-refractory pts (n = 51) in the MMY1001 D-Kd arm, median age was 66 yrs (range 38-85 yrs). Pts had received a median of 2 (range 1-4) prior lines of therapy; 98% had received bortezomib (bort), 18% had received pomalidomide (pom), 43% were refractory to bort, and 18% were refractory to pom. In total, 20 pts (39%) discontinued due to progressive disease (26%), adverse events (AEs; 6%), pt withdrawal (6%), or physician decision (2%). The most common hematologic grade 3/4 treatment-emergent AEs (TEAEs; ≥10%) were thrombocytopenia (37%), anemia (29%), neutropenia (28%), and lymphopenia (26%). Infusion-related reactions were observed in 37% of pts (43% for standard first DARA dose; 36% for split first DARA dose); none were grade 3/4. With 8.3 months of median follow up, median PFS was 14.1 months (95% CI 9.4-not estimable); the 12-month PFS rate was 69% (95% CI 49-82). ORR and MRD-negative rates are summarized in the Table. Median time to MRD negativity (10–5) was 5.1 months. Conclusions: The combination of DARA and weekly Kd was well tolerated and demonstrated promising efficacy in len-refractory pts. Updated data will be presented. Clinical trial information: NCT01998971

%Len refractoryAll
Overall response rate (ORR)a8186
MRD-negative rate

aAmong response-evaluable pts who received > 2 cycles or discontinued treatment.

Other Abstracts in this Sub-Category:


1. Once-weekly vs twice-weekly carfilzomib (K) dosing plus dexamethasone (d) in patients with relapsed and refractory multiple myeloma (RRMM): Results of the randomized phase 3 study A.R.R.O.W.

Meeting: 2018 ASCO Annual Meeting Abstract No: 8000 First Author: Maria-Victoria Mateos
Category: Hematologic Malignancies—Plasma Cell Dyscrasia - Multiple Myeloma


2. Pomalidomide (POM), bortezomib, and low‐dose dexamethasone (PVd) vs bortezomib and low-dose dexamethasone (Vd) in lenalidomide (LEN)-exposed patients (pts) with relapsed or refractory multiple myeloma (RRMM): Phase 3 OPTIMISMM trial.

Meeting: 2018 ASCO Annual Meeting Abstract No: 8001 First Author: Paul G. Richardson
Category: Hematologic Malignancies—Plasma Cell Dyscrasia - Multiple Myeloma


3. Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.

Meeting: 2018 ASCO Annual Meeting Abstract No: 8004 First Author: Luciano J. Costa
Category: Hematologic Malignancies—Plasma Cell Dyscrasia - Multiple Myeloma